IDEXX Laboratories, Inc. IDXX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.21B | 1.22B | 1.14B | 1.09B | 1.11B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.21B | 1.22B | 1.14B | 1.09B | 1.11B |
| Cost of Revenue | 449.94M | 437.50M | 418.08M | 432.47M | 421.89M |
| Gross Profit | 764.30M | 779.09M | 722.74M | 658.11M | 683.35M |
| SG&A Expenses | 293.13M | 288.09M | 294.37M | 266.68M | 265.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 811.89M | 791.02M | 778.23M | 765.97M | 750.39M |
| Operating Income | 402.35M | 425.57M | 362.59M | 324.61M | 354.85M |
| Income Before Tax | 399.33M | 417.22M | 355.44M | 306.98M | 344.77M |
| Income Tax Expenses | 82.18M | 78.81M | 77.00M | 58.79M | 70.16M |
| Earnings from Continuing Operations | 317.15M | 338.41M | 278.45M | 248.19M | 274.61M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 317.15M | 338.41M | 278.45M | 248.19M | 274.61M |
| EBIT | 402.35M | 425.57M | 362.59M | 324.61M | 354.85M |
| EBITDA | 442.91M | 466.62M | 400.27M | 363.33M | 391.47M |
| EPS Basic | 4.02 | 4.29 | 3.50 | 3.11 | 3.43 |
| Normalized Basic EPS | 3.14 | 3.29 | 2.79 | 2.47 | 2.69 |
| EPS Diluted | 4.01 | 4.27 | 3.47 | 3.09 | 3.40 |
| Normalized Diluted EPS | 3.13 | 3.28 | 2.77 | 2.45 | 2.67 |
| Average Basic Shares Outstanding | 78.83M | 78.95M | 79.65M | 79.90M | 80.10M |
| Average Diluted Shares Outstanding | 79.05M | 79.31M | 80.16M | 80.48M | 80.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |